Breaking Finance News

Scotiabank upgraded Concordia International Corp (NASDAQ:CXRX) to Sector Perform in a report released today.

Scotiabank has upgraded Concordia International Corp(NASDAQ:CXRX) to Sector Perform in a report released on Monday September 19 2016.

Yesterday Concordia International Corp (NASDAQ:CXRX) traded 1.20% lower at $5.40. The company’s 50-day moving average is $11.61 and its 200-day moving average is $22.48. The last stock price close is down 76.27% from the two hundred day moving average, compared to the S&P 500 which has fallen -0.01% over the same time period. 702,461 shares of Concordia International Corp exchanged hands, down from ann average trading volume of 848,814.

See Graphic Below:

Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp has a one-year low of $5.01 and a one-year high of $76.10 . Concordia International Corp’s market capitalization is currently $0.0.

In addition to Scotiabank reporting it’s target price, a total of 10 brokerages have issued a research note on the company. The average target stock price is $52.01 with 0 rating the stock a strong buy, 0 rating the company a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 firmsrating the stock as sell.

Brief Synopsis About Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *